Seattle’s Sonoma Biotherapeutics receives $45M milestone payment
Seattle-based Sonoma Biotherapeutics announced it received a $45 million payment from Regeneron Pharmaceuticals for meeting a significant milestone in its efforts to research, develop and commercialize therapies for inflammatory bowel disease and other ailments.
Sonoma is focused on treating autoimmune and inflammatory diseases that cause a person’s immune system to attack the wrong cells. The company is pursuing treatments that use what are known as regulatory T (Treg) cells.